{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T18:50:19Z","timestamp":1788893419052,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Innovation Capacity Building Project, National Engineering Research Center of Foundational Technologies for CGT Industry","award":["NDRC-High-Technology[2023]No. 447 to Muyun Liu"],"award-info":[{"award-number":["NDRC-High-Technology[2023]No. 447 to Muyun Liu"]}]},{"name":"Innovation Capacity Building Project, National Engineering Research Center of Foundational Technologies for CGT Industry","award":["NDRC-High-Technology[2023]No. 447 to Muyun Liu"],"award-info":[{"award-number":["NDRC-High-Technology[2023]No. 447 to Muyun Liu"]}]},{"name":"Innovation Capacity Building Project, National Engineering Research Center of Foundational Technologies for CGT Industry","award":["NDRC-High-Technology[2023]No. 447 to Muyun Liu"],"award-info":[{"award-number":["NDRC-High-Technology[2023]No. 447 to Muyun Liu"]}]},{"name":"Innovation Capacity Building Project, National Engineering Research Center of Foundational Technologies for CGT Industry","award":["NDRC-High-Technology[2023]No. 447 to Muyun Liu"],"award-info":[{"award-number":["NDRC-High-Technology[2023]No. 447 to Muyun Liu"]}]},{"name":"Innovation Capacity Building Project, National Engineering Research Center of Foundational Technologies for CGT Industry","award":["NDRC-High-Technology[2023]No. 447 to Muyun Liu"],"award-info":[{"award-number":["NDRC-High-Technology[2023]No. 447 to Muyun Liu"]}]},{"name":"Innovation Capacity Building Project, National Engineering Research Center of Foundational Technologies for CGT Industry","award":["NDRC-High-Technology[2023]No. 447 to Muyun Liu"],"award-info":[{"award-number":["NDRC-High-Technology[2023]No. 447 to Muyun Liu"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-026-03271-0","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T09:20:07Z","timestamp":1771492807000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Engineered mesenchymal stem cells expressing CXCR4 and LIGHT enhance Anti-Tumor activity in a subcutaneous gastric cancer xenograft model"],"prefix":"10.1007","volume":"43","author":[{"given":"Umer","family":"Anayyat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianbin","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xumin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cui","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muyun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"issue":"3","key":"3271_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"3271_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.111055","volume":"126","author":"F Rastin","year":"2024","unstructured":"Rastin F, et al. Immunotherapy for colorectal cancer: rational strategies and novel therapeutic progress. Int Immunopharmacol. 2024;126:111055.","journal-title":"Int Immunopharmacol"},{"issue":"11","key":"3271_CR3","doi-asserted-by":"publisher","first-page":"9663","DOI":"10.1007\/s11033-023-08809-3","volume":"50","author":"R Kaur","year":"2023","unstructured":"Kaur R, Bhardwaj A, Gupta S. Cancer treatment therapies: traditional to modern approaches to combat cancers. Mol Biol Rep. 2023;50(11):9663\u201376.","journal-title":"Mol Biol Rep"},{"issue":"1","key":"3271_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s13062-024-00549-z","volume":"19","author":"H Cao","year":"2024","unstructured":"Cao H, et al. MIR194-2HG, a miRNA host gene activated by HNF4A, inhibits gastric cancer by regulating MicroRNA biogenesis. Biol Direct. 2024;19(1):95.","journal-title":"Biol Direct"},{"key":"3271_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.114519","volume":"155","author":"M Tarin","year":"2025","unstructured":"Tarin M, et al. Exosomal PD-L1 in non-small cell lung cancer: implications for immune evasion and resistance to immunotherapy. Int Immunopharmacol. 2025;155:114519.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"3271_CR6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13045-023-01451-3","volume":"16","author":"W-L Guan","year":"2023","unstructured":"Guan W-L, He Y, Xu R-H. Gastric cancer treatment: recent progress and future perspectives. J Hematol Oncol. 2023;16(1):57.","journal-title":"J Hematol Oncol"},{"key":"3271_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-025-01570-6","author":"D Li","year":"2025","unstructured":"Li D, et al. EHBMT, a method for visualizing tumor evolution, identifies a surge in gastric cancer with hybrid epithelial\u2013mesenchymal phenotypes due to an inflammatory microenvironment. Exp Mol Med. 2025. https:\/\/doi.org\/10.1038\/s12276-025-01570-6.","journal-title":"Exp Mol Med"},{"issue":"5","key":"3271_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06744-0","volume":"15","author":"S Qin","year":"2024","unstructured":"Qin S, et al. A novel TGFbeta\/TGILR axis mediates crosstalk between cancer-associated fibroblasts and tumor cells to drive gastric cancer progression. Cell Death Dis. 2024;15(5):368.","journal-title":"Cell Death Dis"},{"issue":"10251","key":"3271_CR9","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","volume":"396","author":"EC Smyth","year":"2020","unstructured":"Smyth EC, et al. Gastric cancer. Lancet. 2020;396(10251):635\u201348.","journal-title":"Lancet"},{"issue":"1","key":"3271_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-08029-6","volume":"16","author":"D Li","year":"2025","unstructured":"Li D, et al. Hypermethylation-mediated HNF4A silencing by Helicobacter pylori infection drives gastric cancer by disrupting epithelial cell polarity and activating EMT signaling. Cell Death Dis. 2025;16(1):688.","journal-title":"Cell Death Dis"},{"issue":"4","key":"3271_CR11","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1080\/1061186X.2024.2433551","volume":"33","author":"M Akbari Oryani","year":"2025","unstructured":"Akbari Oryani M, et al. Synergistic cancer treatment using porphyrin-based metal-organic frameworks for photodynamic and photothermal therapy. J Drug Target. 2025;33(4):473\u201391.","journal-title":"J Drug Target"},{"key":"3271_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2020.00043","volume":"8","author":"A Hmadcha","year":"2020","unstructured":"Hmadcha A, et al. Therapeutic potential of mesenchymal stem cells for cancer therapy. Front Bioeng Biotechnol. 2020;8:43.","journal-title":"Front Bioeng Biotechnol"},{"issue":"6","key":"3271_CR13","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1080\/1061186X.2025.2467139","volume":"33","author":"F Attarian","year":"2025","unstructured":"Attarian F, et al. Role of liposomes in chemoimmunotherapy of breast cancer. J Drug Target. 2025;33(6):887\u2013915.","journal-title":"J Drug Target"},{"issue":"12","key":"3271_CR14","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1038\/s41417-020-0179-6","volume":"27","author":"M Mosallaei","year":"2020","unstructured":"Mosallaei M, et al. Genetically engineered mesenchymal stem cells: targeted delivery of immunomodulatory agents for tumor eradication. Cancer Gene Ther. 2020;27(12):854\u201368.","journal-title":"Cancer Gene Ther"},{"issue":"5","key":"3271_CR15","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1097\/SLA.0b013e3182368c4f","volume":"254","author":"H Niess","year":"2011","unstructured":"Niess H, et al. Selective targeting of genetically engineered mesenchymal stem cells to tumor stroma microenvironments using tissue-specific suicide gene expression suppresses growth of hepatocellular carcinoma. Ann Surg. 2011;254(5):767\u201375.","journal-title":"Ann Surg"},{"issue":"1","key":"3271_CR16","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jcyt.2012.10.003","volume":"15","author":"JL Dembinski","year":"2013","unstructured":"Dembinski JL, et al. Tumor stroma engraftment of gene-modified mesenchymal stem cells as anti-tumor therapy against ovarian cancer. Cytotherapy. 2013;15(1):20\u201332. e2.","journal-title":"Cytotherapy"},{"issue":"1","key":"3271_CR17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.5430\/dcc.v11n1p25","volume":"11","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, et al. Research progress on the effect of human umbilical cord mesenchymal stem cells (hUC-MSCs) on lung cancer. Discussion Clin Cases. 2024;11(1):25\u20139.","journal-title":"Discussion Clin Cases"},{"issue":"20","key":"3271_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13205216","volume":"13","author":"J Koerfer","year":"2021","unstructured":"Koerfer J, Lordick F, Hacker UT. Molecular targets for gastric cancer treatment and future perspectives from a clinical and translational point of view. Cancers. 2021;13(20):5216.","journal-title":"Cancers"},{"key":"3271_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00922","volume":"11","author":"JG Skeate","year":"2020","unstructured":"Skeate JG, et al. TNFSF14: lighting the way for effective cancer immunotherapy. Front Immunol. 2020;11:922.","journal-title":"Front Immunol"},{"issue":"1","key":"3271_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-11-70","volume":"11","author":"JZ Qin","year":"2013","unstructured":"Qin JZ, et al. Shedding LIGHT (TNFSF14) on the tumor microenvironment of colorectal cancer liver metastases. J Transl Med. 2013;11(1):70.","journal-title":"J Transl Med"},{"key":"3271_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2024.101315","author":"M Tridgett","year":"2024","unstructured":"Tridgett M, et al. Lentiviral vector packaging and producer cell lines yield titers equivalent to the industry-standard four-plasmid process. Mol Ther. 2024. https:\/\/doi.org\/10.1016\/j.omtm.2024.101315.","journal-title":"Mol Ther"},{"issue":"1","key":"3271_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/srep09021","volume":"5","author":"KS Sanber","year":"2015","unstructured":"Sanber KS, et al. Construction of stable packaging cell lines for clinical lentiviral vector production. Sci Rep. 2015;5(1):9021.","journal-title":"Sci Rep"},{"issue":"9","key":"3271_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.23361","volume":"34","author":"AM Cornel","year":"2020","unstructured":"Cornel AM, et al. FACSCanto II and LSRFortessa flow cytometer instruments can be synchronized utilizing single-fluorochrome\u2013conjugated surface\u2010dyed beads for standardized immunophenotyping. J Clin Lab Anal. 2020;34(9):e23361.","journal-title":"J Clin Lab Anal"},{"issue":"6","key":"3271_CR24","doi-asserted-by":"publisher","first-page":"e0157762","DOI":"10.1371\/journal.pone.0157762","volume":"11","author":"S Knutson","year":"2016","unstructured":"Knutson S, et al. Development and evaluation of a fluorescent antibody-drug conjugate for molecular imaging and targeted therapy of pancreatic cancer. PLoS One. 2016;11(6):e0157762.","journal-title":"PLoS One"},{"issue":"8","key":"3271_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/nu15082006","volume":"15","author":"J de Freitas Rodrigues","year":"2023","unstructured":"de Freitas Rodrigues J, et al. The potential of DHA as cancer therapy strategies: a narrative review of in vitro cytotoxicity trials. Nutrients. 2023;15(8):2006.","journal-title":"Nutrients"},{"issue":"3","key":"3271_CR26","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1002\/fft2.44","volume":"1","author":"S Kamiloglu","year":"2020","unstructured":"Kamiloglu S, et al. Guidelines for cell viability assays. Food Front. 2020;1(3):332\u201349.","journal-title":"Food Front"},{"key":"3271_CR27","volume":"133","author":"F Cappiello","year":"2018","unstructured":"Cappiello F, Casciaro B, Mangoni ML. A novel in vitro wound healing assay to evaluate cell migration. Journal of visualized experiments: JoVE. 2018;133:56825.","journal-title":"Journal of visualized experiments: JoVE"},{"key":"3271_CR28","doi-asserted-by":"publisher","first-page":"pdbprot087288","DOI":"10.1101\/pdb.prot087288","volume":"201611","author":"LC Crowley","year":"2016","unstructured":"Crowley LC, et al. Quantitation of apoptosis and necrosis by Annexin V binding, Propidium iodide uptake, and flow cytometry. Cold Spring Harbor Protoc. 2016;201611:pdbprot087288.","journal-title":"Cold Spring Harbor Protoc"},{"key":"3271_CR29","doi-asserted-by":"publisher","unstructured":"Tarin M, et al. Advancements in chitosan-based nanocomposites with ZIF-8 nanoparticles: multifunctional platforms for wound healing applications. Carbohydr Polym. 2025; 362. https:\/\/doi.org\/10.1016\/j.carbpol.2025.123656","DOI":"10.1016\/j.carbpol.2025.123656"},{"issue":"4","key":"3271_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0192744","volume":"13","author":"Y Iseki","year":"2018","unstructured":"Iseki Y, et al. A new method for evaluating tumor-infiltrating lymphocytes (TILs) in colorectal cancer using hematoxylin and eosin (HE)-stained tumor sections. PLoS One. 2018;13(4):e0192744.","journal-title":"PLoS One"},{"issue":"5","key":"3271_CR31","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1007\/s13346-023-01469-7","volume":"14","author":"S Yu","year":"2024","unstructured":"Yu S, et al. Anticancer effect of hUC-MSC-derived exosome-mediated delivery of PMO-miR-146b-5p in colorectal cancer. Drug Delivery Translational Res. 2024;14(5):1352\u201369.","journal-title":"Drug Delivery Translational Res"},{"issue":"4","key":"3271_CR32","doi-asserted-by":"publisher","first-page":"611","DOI":"10.7150\/jca.77905","volume":"14","author":"M Wang","year":"2023","unstructured":"Wang M, et al. Inhibition of STAT3 signaling as critical molecular event in HUC-MSCs suppressed glioblastoma cells. J Cancer. 2023;14(4):611.","journal-title":"J Cancer"},{"issue":"14","key":"3271_CR33","doi-asserted-by":"publisher","first-page":"7371","DOI":"10.3390\/ijms22147371","volume":"22","author":"T Khare","year":"2021","unstructured":"Khare T, Bissonnette M, Khare S. CXCL12-CXCR4\/CXCR7 axis in colorectal cancer: therapeutic target in preclinical and clinical studies. Int J Mol Sci. 2021;22(14):7371.","journal-title":"Int J Mol Sci"},{"key":"3271_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1025286","volume":"13","author":"M Han","year":"2022","unstructured":"Han M, et al. Comprehensive characterization of TNFSF14\/LIGHT with implications in prognosis and immunotherapy of human gliomas. Front Immunol. 2022;13:1025286.","journal-title":"Front Immunol"},{"key":"3271_CR35","doi-asserted-by":"crossref","unstructured":"Lourenco S, Maughan E, Janes S. MSC homing & Immunomodulatory properties in cancer therapies: searching for the perfect balance. Cell and Gene Therapy Insights; 2015.","DOI":"10.18609\/cgti.2015.024"},{"key":"3271_CR36","doi-asserted-by":"publisher","DOI":"10.21037\/sci-2022-025","volume":"9","author":"DS Baranovskii","year":"2022","unstructured":"Baranovskii DS, et al. Adverse events, side effects and complications in mesenchymal stromal cell-based therapies. Stem Cell Investig. 2022;9:7.","journal-title":"Stem Cell Investig"},{"issue":"11","key":"3271_CR37","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1080\/17425247.2021.1960309","volume":"18","author":"Y Takayama","year":"2021","unstructured":"Takayama Y, Kusamori K, Nishikawa M. Mesenchymal stem\/stromal cells as next-generation drug delivery vehicles for cancer therapeutics. Expert Opin Drug Deliv. 2021;18(11):1627\u201342.","journal-title":"Expert Opin Drug Deliv"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03271-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-026-03271-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03271-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T12:03:58Z","timestamp":1775649838000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-026-03271-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":37,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["3271"],"URL":"https:\/\/doi.org\/10.1007\/s12032-026-03271-0","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,19]]},"assertion":[{"value":"10 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Human umbilical cord-derived MSCs were gratis provided by Shenzhen Beike Biotechnology Co., Ltd. Ethical approval and informed consent for this study were obtained from Safety and Ethics Committee at Shenzhen Beike Biotechnology Co., Ltd (approval number: BK-SL-202403 14\u2009\u2212\u200901 & BK-DWLL-2025-0013)According to the manufacturer, the MSCs were isolated and cultured from the Wharton\u2019s ielly of umbilical cords of maternal volunteers.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"155"}}